title: Moclobemide excretion in human breast milk.
abstract: 1. Six lactating white women, aged 24-36 years, received a single oral dose of 300 mg moclobemide, between 09.00 h and 11.00 h, 3 to 5 days after the delivery of a full term neonate. 2. Complete milk collections were obtained before, 3, 6, 9, 12 and 24 h after drug administration by means of a breast pump. Venous blood samples were drawn before, and 0.5, 1, 3, 4.5, 6, 9, 12, 24 h post-dosing. 3. Moclobemide, and its major metabolite (Ro 12-8095) were measured in milk and plasma samples using h.p.l.c. The active metabolite (Ro 12-5637) could only be detected in plasma. 4. Moclobemide and its metabolites were not detectable in 24 h plasma samples. Cmax, tmax and t1/2 for moclobemide were (mean +/- s.d.) 2.70 +/- 1.24 mg l-1, 2.03 +/- 1.19 h and 2.26 +/- 0.26 h, respectively. 5. The concentrations of moclobemide and Ro 12-8095 in milk were highest at 3 h after drug administration and the drug and metabolite were not detectable after 12 h. Ro 12-5637 was not detected in any milk sample. The percentages of the dose excreted as moclobemide and Ro 12-8095 were (mean +/- s.d.) 0.057 +/- 0.020% and 0.031 +/- 0.011%, respectively. An average 3.5 kg breast-fed neonate would therefore be exposed to only a 0.05 mg kg-1 moclobemide dose (approximately 1% of the maternal dose on the mg kg-1 basis). The low amount of moclobemide excreted into breast milk is unlikely to be hazardous to suckling infants.
authors.affiliation: Département de Pharmacologie Clinique Périnatale et Pédiatrique, Hôpital Saint-Vincent de Paul, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Pons
authors.forename: M P
authors.initials: MP
authors.lastname: Schoerlin
authors.forename: Y K
authors.initials: YK
authors.lastname: Tam
authors.forename: C
authors.initials: C
authors.lastname: Moran
authors.forename: J P
authors.initials: JP
authors.lastname: Pfefen
authors.forename: C
authors.initials: C
authors.lastname: Francoual
authors.forename: A M
authors.initials: AM
authors.lastname: Pedarriosse
authors.forename: J
authors.initials: J
authors.lastname: Chavinie
authors.forename: G
authors.initials: G
authors.lastname: Olive
mesh_terms: D000328:Adult; D001549:Benzamides / Q000378:metabolism / Q000493:pharmacokinetics*; D001682:Biological Availability; D001711:Biotransformation; D005260:Female; D006801:Humans; D008895:Milk, Human / Q000378:metabolism*; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000378:metabolism / Q000493:pharmacokinetics*; D009025:Morpholines / Q000378:metabolism
chemical_list: D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D009025:Morpholines; C062936:Ro 12-5637; C062937:Ro 12-8095; D020912:Moclobemide